Mergers & Acquisitions - Cardio-vascular

Filter

Current filters:

Cardio-vascular

Popular Filters

1 to 25 of 28 results

Luye Pharma to acquire majority stake in Beijing Jialin for $599 million

Luye Pharma to acquire majority stake in Beijing Jialin for $599 million

03-09-2014

Hong Kong-based Luye Pharma has entered into an agreement to purchase a 57.98% stake of Beijing Jialin…

Beijing Jialin PharmaceuticalCardio-vascularChinaLuye PharmaMergers & AcquisitionsPharmaceutical

uniQure acquires cardiology gene therapy firm InoCard

12-08-2014

Netherlands-based human gene therapy firm uniQure says it has acquired Germany’s InoCard GmbH, an innovative,…

BiotechnologyCardio-vascularGermanyInoCardMergers & AcquisitionsNetherlandsuniQure

AstraZeneca stresses confidence in independence, highlighting strong R&D pipeline

15-05-2014

Anglo-Swedish pharma major AstraZeneca, the subject of the controversial takeover attempt by Pfizer,…

AstraZenecaCardio-vascularMergers & AcquisitionsMetabolicsOncologyPharmaceuticalResearchRespiratory and Pulmonary

Retrophin to acquire Manchester Pharma in $62.5 million deal

Retrophin to acquire Manchester Pharma in $62.5 million deal

13-02-2014

USA-based Retrophin has signed an agreement to acquire Manchester Pharmaceuticals, a privately-held specialty…

Cardio-vascularChenodalManchester PharmaceuticalsMergers & AcquisitionsPharmaceuticalRare diseasesRetrophinVecamyl

Oxygen Biotherapeutics signs agreement to acquire Phase III cardiac drug from Phyxius Pharma

22-10-2013

US drug developer Oxygen Biotherapeutics has signed a Definitive Agreement to acquire certain assets…

Cardio-vascularLevosimendanLicensingMergers & AcquisitionsNorth AmericaOxygen BiotherapeuticsPharmaceutical

GlaxoSmithKline agrees £700 million deal with Aspen

GlaxoSmithKline agrees £700 million deal with Aspen

30-09-2013

GlaxoSmithKline says it has now reached agreement to sell its thrombosis brands, Arixtra and Fraxiparine,…

ArixtraAspen PharmacareCardio-vascularFraxiparineGlaxoSmithKlineMergers & AcquisitionsPharmaceuticalRest of the World

Serodus to acquire Phlogo to expand cardiovascular portfolio

12-07-2013

Norwegian biopharma company Serodus (Oslo Axess: SER) says that, following approval by an extraordinary…

BiotechnologyCardio-vascularMergers & AcquisitionsPhlogoSER130SER140Serodus

XOMA transfers perindopril franchise rights to Symplmed

08-07-2013

California, USA-based XOMA Corp (Nasdaq: XOMA) says it has transferred US development and commercialization…

Cardio-vascularLicensingMergers & AcquisitionsperindoprilPharmaceuticalServierSymplmedXOMA Corp

Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site

19-06-2013

UK pharma giant GlaxoSmithKline (LSE: GSK) said yesterday (June 18) that it has received an offer for…

ArixtraAspen PharmacareCardio-vascularFraxiparineGlaxoSmithKlineMergers & AcquisitionsPharmaceuticalProduction

AstraZeneca to buy Omthera in up to $443 million deal

28-05-2013

Anglo-Swedish drug major AstraZeneca's (LSE: AZN) new chief executive Pascal Soriot is making another…

AstraZenecaCardio-vascularEpanovaMergers & AcquisitionsOmthera PharmaceuticalsPharmaceutical

AstraZeneca acquires AlphaCore; Merck Serono links with BioMed X

03-04-2013

In line with its stated policy of targeted acquisitions, Anglo-Swedish drug major AstraZeneca (LSE: AZN)…

AlphaCore PharmaAstraZenecaBiotechnologyCardio-vascularMerck KGaAMerck SeronoMergers & AcquisitionsMetabolicsPharmaceuticalResearch

US FDA clears Amarin's Vascepa, a competitor for Lovaza

30-07-2012

The US Food and Drug Administration has approved biotech firm Amarin's (Nasdaq: AMRN) Vascepa (icosapent…

AmarinBiotechnologyCardio-vascularGlaxoSmithKlineLovazaMergers & AcquisitionsNorth AmericaRegulationVascepa

Janssen buys Germany's CorImmun

29-06-2012

US health care giant Johnson & Johnson's (NYSE: JNJ) European subsidiary Janssen-Cilag GmbH yesterday…

Cardio-vascularCorImmun GmbHJanssenJohnson & JohnsonMergers & AcquisitionsPharmaceutical

Cornerstone makes $125 million, plus, bid for EKR Thera

16-05-2012

In a second acquisition move within a matter of months, USA-based specialty drugmaker Cornerstone Therapeutics…

Cardio-vascularCornerstone TherapeuticsEKR TherapeuticsMergers & AcquisitionsPharmaceutical

Mylan gets OK for generic Crestor in Canada; Rottapharm deal looks dead

18-03-2012

The Canadian subsidiary of US generic drugmaker Mylan (Nasdaq: MYL) has received approval from Health…

AstraZenecaCardio-vascularCrestorEuropeGenericsMergers & AcquisitionsMylan LaboratoriesNorth AmericaPharmaceuticalRegulationRottapharm

Lundbeck buys remaining rights to desmoteplase from Paion

29-02-2012

Danish CNS drug specialist Lundbeck A/S (LUND: DC) and Germany’s Paion AG (FSE: PA8) have entered…

Cardio-vasculardesmoteplaseLundbeckMergers & AcquisitionsPaionPharmaceutical

Karo Bio drops eprotirome and split up plans

15-02-2012

There was a double-dose of bad news for Sweden’s Karo Bio (STO: KARO), which this week said it would…

BiotechnologyCardio-vasculareprotiromeKaro BioMergers & AcquisitionsPharmaceuticalRegulation

Hikma adds to stake in Promopharm; gets US appro for argatroban

22-01-2012

Fast-growing Jordan headquartered Hikma Pharmaceuticals (LSE: HIK) says that it has increased its stake…

ArgatrobanCardio-vascularGenericsHikma PharmaceuticalsMergers & AcquisitionsNorth AmericaPharmaceuticalPromopharmRegulationRest of the World

1 to 25 of 28 results

Back to top